Pluvicto & Metastatic Prostate Cancer

Pluvicto is approved for patients with PSMA-positive metastatic prostate cancer at multiple stages of the disease. Eligibility depends on your diagnosis, imaging findings, prior treatments, and clinical review.

For patients with metastatic hormone-sensitive prostate cancer (mHSPC):

• Diagnosis of PSMA-positive mHSPC (confirmed via a PSMA PET scan)
• Pluvicto is administered in combination with an androgen receptor pathway inhibitor (ARPI)

For patients with metastatic castration-resistant prostate cancer (mCRPC):

• Diagnosis of PSMA-positive mCRPC (confirmed via a PSMA PET scan)
• Prior treatment with an androgen receptor pathway inhibitor

Our team will work closely with you and your referring physician to evaluate your eligibility. We are committed to guiding you through every step of this journey, ensuring clarity and confidence in your treatment plan.

PLUVICTO® combines the radioisotope Lutetium-177, with a PSMA-targeting molecule. The therapy seeks out PSMA proteins in prostate cancer cells, delivering a highly localized dose of radiation that damages the DNA within these cells. This approach minimizes harm to surrounding healthy tissue, offering a more precise and effective treatment option.

Like any cancer therapy, PLUVICTO® may cause side effects. The most commonly reported include:

• Fatigue or decreased energy.
• Nausea or dry mouth.
• Mild to moderate changes in blood counts (e.g., anemia).
• Reduced appetite or constipation.

Our medical team is here to help you manage these symptoms effectively. We will proactively monitor your health throughout treatment and adjust your care plan as needed.

Because PLUVICTO® involves radiation, small amounts may pass through bodily fluids (e.g., urine or saliva). To minimize exposure to loved ones:

• Practice good hygiene, such as washing hands thoroughly and frequently.
• Avoid close contact with pregnant women or young children for a few days post-treatment.
• Follow specific safety guidelines provided by our team.

At United Theranostics, we prioritize education and safety to ensure you and your family feel informed and at ease.

We believe in precision care at every step. During your treatment, we’ll:

• Perform regular blood tests to monitor kidney function, blood counts, and overall health.
• Use advanced imaging (like PSMA PET scans) to assess the therapy’s effectiveness.
• Hold frequent consultations to review your progress and address any concerns.

This collaborative approach ensures your treatment remains on track and caters to your body and cancer’s needs.

Getting started is simple. You can:

• Contact United Theranostics directly to schedule a consultation.
• Request a referral from your oncologist or primary care physician.

During your consultation, we’ll review your medical history, confirm your PSMA-positive status with a PET scan, and design a treatment plan tailored to your needs.

Coverage for PLUVICTO® varies depending on your insurance provider. At United Theranostics, we have a dedicated team to:

• Verify your insurance benefits.
• Assist with pre-authorizations.
• Explore financial assistance programs for eligible patients.

We are committed to making this life-changing therapy accessible to everyone who needs it.

To keep your loved ones safe, avoid close contact (less than 3 feet) with others for the first two days after treatment. Avoid contact with children and pregnant individuals for seven days. Additionally, it’s recommended to sleep in a separate room from others for at least three days and up to 15 days if your household includes pregnant individuals.

Staying hydrated is key after PLUVICTO®. Drinking plenty of water helps your body eliminate any residual radioactivity through urine. Frequent urination during the first 24 hours after treatment is encouraged to support this process.

Common side effects include fatigue, dry mouth, nausea, or changes in appetite. You may also notice mild changes in bowel movements or low blood counts. Contact your healthcare provider if you experience severe or prolonged symptoms; they can help manage any concerns.

Most patients can resume regular activities within a few days. Your healthcare team will provide specific instructions based on your health and treatment, but taking it easy during the first few days can help you recover.